

NE/I
5/21/07
ck

In the Claims

Claims 1-9 are canceled.

1 ~~10~~. (currently amended) The compound of ~~Claim 7~~ selected from the group consisting of


(2R)-6-chloro-7-isobutyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
6-chloro-7-isobutyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
(2R)-7-benzyl-6-chloro-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
7-benzyl-6-chloro-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
7-butoxy-6-chloro-8-methyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
7-benzyl-6-bromo-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
7-butyl-6-chloro-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
6,8-dichloro-7-(2-ethylbutoxy)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
6-chloro-8-methyl-7-propoxy-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
6-chloro-7-(isobutylthio)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
6-chloro-7-(2-ethylbutoxy)-8-methyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
6-chloro-7-(isopentyloxy)-8-methyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
8-methyl-6-(trifluoromethoxy)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
6,8-dichloro-7-isobutoxy-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
~~8-chloro-6-iodo-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;~~
7-benzyl-6-methyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
7-(sec-butylthio)-6-chloro-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;

acid;
(2S)-6-ethyl-8-methyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
~~6,8-dichloro-6-methyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;~~
6-chloro-8-(4-chloro-3-methylphenyl)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
8-ethyl-6-(trifluoromethoxy)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
~~(2S)-6-chloro-8-methyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;~~
(2S)-8-ethyl-6-(trifluoromethoxy)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
(2S)-6-chloro-5,7-dimethyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
6-chloro-8-(4-methylphenyl)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
6-chloro-8-(3-fluoro-4-methylphenyl)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
8-propyl-6-(trifluoromethoxy)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;

5-bromo-6,7-dichloro-8-methoxy-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
 6-chloro-8-(4-ethylphenyl)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid; and
 (2S)-6,8-dimethyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid;
 or their isomer and pharmaceutically acceptable salt thereof.

Claims 11-26 are canceled.

27. (withdrawn) A method for the treatment or prevention of a COX-2 mediated disorder in a subject in need of such treatment or prevention, wherein the method comprises administering to the subject an amount of a compound of Formula 1



or a pharmaceutically acceptable salt thereof,

wherein:

X is selected from the group consisting of H, alkyl, and a pharmaceutically acceptable cation;

Z is selected from the group consisting of O, S and NH;

wherein R¹, R², R³, and R⁴ are each independently selected from the group consisting of H, alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonylalkyl, alkyl, alkylamino, alkylcarbonyl, alkylheteroaryl, alkylsulfonylalkyl, alkylthio, alkynyl, aminocarbonylalkyl, aryl, arylalkenyl, arylalkoxy, arylalkyl, arylalkylamino, arylalkynyl, arylcarbonyl, aryloxy, cyano, dialkylamino, halo, haloalkoxy, haloalkyl, heteroaryl, heteroarylalkoxy, heteroarylcarbonyl, hydroxy and hydroxyalkyl; wherein each of aryl, wherever it occurs, is independently substituted with one to five substituents selected from the group consisting of alkyl, alkoxy, alkylamino, cyano, halo, haloalkyl, hydroxy, and nitro; wherein the amount of the compound is effective for the treatment or prevention of the COX-2 mediated disorder.

28. (withdrawn) A method of Claim 27 wherein the COX-2 mediated disorder is an inflammatory disorder.

29. (withdrawn) A method of Claim 27 wherein the COX-2 mediated disorder is a neoplasia.

30. (withdrawn) A method of Claim 27 wherein the COX-2 mediated disorder is an ophthalmic disorder.

31. (withdrawn) A method of Claim 27 wherein the COX-2 mediated disorder is a cardiovascular disorder.

32. (withdrawn) A method of Claim 27 wherein the COX-2 mediated disorder is schizophrenia.

33. (withdrawn) A method of Claim 26 wherein the COX-2 mediated disorder is schizophrenia.
